[go: up one dir, main page]

PE68799A1 - Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina - Google Patents

Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina

Info

Publication number
PE68799A1
PE68799A1 PE1998000326A PE00032698A PE68799A1 PE 68799 A1 PE68799 A1 PE 68799A1 PE 1998000326 A PE1998000326 A PE 1998000326A PE 00032698 A PE00032698 A PE 00032698A PE 68799 A1 PE68799 A1 PE 68799A1
Authority
PE
Peru
Prior art keywords
dopamine
compound
carboxamide
alkyl
refers
Prior art date
Application number
PE1998000326A
Other languages
English (en)
Inventor
Clive Leslie Branch
Christopher Norbert Johnson
Geoffrey Stemp
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9708976.7A external-priority patent/GB9708976D0/en
Priority claimed from GBGB9723294.6A external-priority patent/GB9723294D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE68799A1 publication Critical patent/PE68799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) Y SUS SALES; DONDE, R1 ES H, HALOGENO, HIDROXI, R3R4NSO2(CH2)p, ENTRE OTROS; R3 Y R4 SON INDEPENDIENTEMENTE H O ALQUILO C1-C4, UN ANILLO AZACICLOALCANO C3-C6, ENTRE OTROS; p ES CERO-4; R2 ES H O ALQUILO C1-C4; q ES 1 o 2; "A" ES -Ar, -Ar1-Y-Ar2, -CH=CH-Ar; Ar ES FENILO, HETEROCICLO DE 5-6 MIEMBROS, ANILLO BICICLICO OPCIONALMENTE SUSTITUIDO; Ar1 Y Ar2 SON FENILO, ANILLO AROMATICO HETEROCICLICO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO; "Y" ES UN ENLACE, -NHCO-, -CONH-, -CH2-, ENTRE OTROS; CUANDO "A" ES -Ar, UN SUSTITUYENTE EN POSICION ORTO RESPECTO AL RESTO CARBOXAMIDA ES H o METOXI. UN COMPUESTO PREFERIDO ES TRANS-6-CIANO-2-(2-(1-(4-(4-QUINOLINIL)CARBOXAMIDO)CICLOHEXIL)ETIL)-1,2,3,4-TETRAHIDROISOQUINOLEINA Y LA SAL MONOHIDROCLORURO O MONOMESILATO, ENTRE OTROS. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION. EL COMPUESTO DE FORMULA (I) MODULA EL RECEPTOR DOPAMINA D3 ACTUANDO COMO AGONISTA, PUDIENDO SER UTIL EN EL TRATAMIENTO DE CONDICION PSICOTICA COMO LA ESQUIZOFRENIA
PE1998000326A 1997-05-03 1998-04-29 Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina PE68799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9708976.7A GB9708976D0 (en) 1997-05-03 1997-05-03 Compounds
GBGB9723294.6A GB9723294D0 (en) 1997-11-04 1997-11-04 Compounds

Publications (1)

Publication Number Publication Date
PE68799A1 true PE68799A1 (es) 1999-09-26

Family

ID=26311476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000326A PE68799A1 (es) 1997-05-03 1998-04-29 Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina

Country Status (17)

Country Link
US (1) US6465485B1 (es)
EP (1) EP0983244A1 (es)
JP (1) JP2002501506A (es)
CN (1) CN1261350A (es)
AR (1) AR013078A1 (es)
AU (1) AU725491B2 (es)
BR (1) BR9809591A (es)
CA (1) CA2288899A1 (es)
HU (1) HUP0003608A3 (es)
IL (1) IL132631A0 (es)
MA (1) MA26490A1 (es)
NO (1) NO995338D0 (es)
PE (1) PE68799A1 (es)
PL (1) PL336628A1 (es)
TR (1) TR199902724T2 (es)
UY (1) UY24986A1 (es)
WO (1) WO1998050364A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US6429207B1 (en) * 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1037878A2 (en) * 1997-11-21 2000-09-27 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
GB9810876D0 (en) * 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
GB9812522D0 (en) * 1998-06-10 1998-08-05 Smithkline Beecham Plc Compounds
US6855717B2 (en) * 1998-06-10 2005-02-15 Smithkline Beecham, Plc Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
CN1329609A (zh) * 1998-10-08 2002-01-02 史密丝克莱恩比彻姆有限公司 用作多巴胺d3受体调制剂(精神抑制药)的四氢苯并氮杂䓬衍生物
GB9821978D0 (en) * 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
GB9821977D0 (en) * 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
WO2003068732A2 (en) * 2002-02-13 2003-08-21 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
JP2009511530A (ja) * 2005-10-13 2009-03-19 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する５−キノリン誘導体
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010040274A1 (zh) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9045478B2 (en) 2011-12-12 2015-06-02 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
LT3448859T (lt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Pirolpirolo kompozicijos, kaip piruvato kinazės (pkr) aktyvatoriai
JPWO2019146739A1 (ja) * 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
AU2020349555A1 (en) 2019-09-19 2022-04-07 Forma Therapeutics, Inc. Activating Pyruvate Kinase R
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220778A (en) * 1978-10-30 1980-09-02 G. D. Searle & Co. 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
FR2706895A1 (en) * 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
AU6859096A (en) 1995-09-22 1997-04-09 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
ES2191838T3 (es) * 1996-05-11 2003-09-16 Smithkline Beecham Plc Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina.
ES2154470T3 (es) * 1996-08-14 2001-04-01 Smithkline Beecham Plc Derivados de tetrahidroisoquinolina y su uso farmaceutico.
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
AU7651898A (en) 1998-11-27
NO995338L (no) 1999-11-02
HUP0003608A2 (en) 2001-03-28
US6465485B1 (en) 2002-10-15
NO995338D0 (no) 1999-11-02
PL336628A1 (en) 2000-07-03
AR013078A1 (es) 2000-12-13
JP2002501506A (ja) 2002-01-15
IL132631A0 (en) 2001-03-19
CN1261350A (zh) 2000-07-26
MA26490A1 (fr) 2004-12-20
AU725491B2 (en) 2000-10-12
BR9809591A (pt) 2001-09-11
HUP0003608A3 (en) 2001-06-28
EP0983244A1 (en) 2000-03-08
TR199902724T2 (xx) 2000-04-21
CA2288899A1 (en) 1998-11-12
UY24986A1 (es) 2001-08-27
WO1998050364A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
PE68799A1 (es) Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
PE20010543A1 (es) Derivados de purina como inhibidores de tirosincinasa syk
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20000728A1 (es) Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
PE20010759A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20031011A1 (es) Derivados de dihidrobenzodiazepin-2-ona-iii
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE97799A1 (es) Derivados de piridina
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
CO5670367A2 (es) Derivados de acido fenoxiacetico
ECSP066609A (es) Uso de derivados de n-arilhidracina para combatir pestes
PE20000170A1 (es) Derivados benzosulfonas
PT87183A (pt) Procede de preparation de derives d:aryl-heteroaryl carbinol avec activite analgesique
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
BR0009278A (pt) 1-arenossulfonil-2-aril-pirrolidina e derivados depiperidina
ATE171162T1 (de) 5-(2-oxyphenyl)-pyrrol-derivate als dopamin-d3- rezeptor-antagonisten
KR880003920A (ko) 피리다지논 유도체
PE20001598A1 (es) Derivados de n-[2-(4-aminofenil)etil]-2,3-dihidro-1,4-benzodioxin-2-metanamina
ATE253058T1 (de) Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
PE20081495A1 (es) Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed